0001209191-19-014296.txt : 20190227 0001209191-19-014296.hdr.sgml : 20190227 20190227201746 ACCESSION NUMBER: 0001209191-19-014296 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190225 FILED AS OF DATE: 20190227 DATE AS OF CHANGE: 20190227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Macrae Sandy CENTRAL INDEX KEY: 0001675687 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 19639965 MAIL ADDRESS: STREET 1: 721 ST. GEORGES ROAD CITY: PHILADELPHIA STATE: PA ZIP: 19119 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 501 CANAL BLVD STREET 2: POINT RICHMOND TECH CNTR. CITY: RICHMOND STATE: CA ZIP: 94804 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 501 CANAL BLVD STREET 2: POINT RICHMOND TECH CNTR. CITY: RICHMOND STATE: CA ZIP: 94804 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-02-25 0 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001675687 Macrae Sandy C/O SANGAMO THERAPEAUTICS, INC. POINT RICHMOND TECH CTR, 501 CANAL BLVD. RICHMOND CA 94804 1 1 0 0 President and CEO Common Stock 2019-02-25 4 A 0 63250 0.00 A 90776 D Stock Option (Right-to-Buy) 9.03 2019-02-25 4 A 0 379500 0.00 A 2029-02-24 Common Stock 379500 379500 D Represents 63,250 shares subject to restricted stock units granted on February 25, 2019 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Additionally, this amount includes 21,000 shares subject to restricted stock units granted on January 24, 2018 that will vest in two (2) remaining equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2019 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. /s/ Denise Winn, Attorney-in-Fact for Sandy Macrae 2019-02-27